Discontinuation of higher laquinimod doses in two MS trials

January 2016
Reactions Weekly;1/16/2016, Vol. 1584 Issue 1, p1
An abstract is presented of the article "Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials" published on January 4, 2016 on the website www.tevapharm.com.


Related Articles

  • Teva and Active Biotech amend marketing and distribution agreement.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p5 

    The author reflects on the gap that exists in the orally administered treatments for relapsing multiple sclerosis (MS). He asserts that laquinomoid, an autoimmune suppressant used for treating relapsing MS, is behind from other oral MS treatments in the clinical trial process. He stresses that...

  • Teva, Active Down Following Laquinimod Phase III Miss. Wall, Tom // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p1 

    The article reports on the decline in stocks of pharmaceutical companies Active Biotech AB and Teva Pharmaceutical Industries Ltd. It states that the decline came as a result of the announcement that laquinimod, an oral multiple sclerosis drug, failed to decrease the annualized relapse rate in...

  • Teva's MS Drug Nails Primary Endpoints -- and Then Some. Powers, Marie // BioWorld Today;12/10/2010, Vol. 21 Issue 238, p1 

    The article reports on the result of the two-year Phase III ALLEGRO study of the oral laquinimod for relapsing-remitting multiple sclerosis (RRMS) developed by Teva Pharmaceuticals which demonstrated a significant reduction in annualized relapse rate compared to placebo. The drug, which Teva is...

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15 

    The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral...

  • Active's MAA for multiple sclerosis drug receives EMA acceptance for review.  // PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p10 

    The article reports on the announcement made by Active Biotech regarding the completion by the European Medicines Agency (EMA) of the marketing authorization application (MAA) validation process and acceptance for review of laquinimod for the treatment of relapsing-remitting multiple sclerosis...

  • Multiple Sclerosis.  // PharmaWatch: CNS;November 2003, Vol. 2 Issue 11, p17 

    Reports on developments relating to multiple sclerosis (MS) treatment. Phase II of Active Biotech's multiple sclerosis drug; Positive long-term results for MS patients shown by Serono's Rebif drug; Study showing long-term effect of Biogen's MS drug.

  • Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p121 

    The article reports on the presentation of data from a study conducted by Teva Pharmaceutical Industries Ltd. and Active Biotech AB on the potential of laquinod in treating multiple sclerosis. The findings of the phase III study suggests the effectiveness of laquinimod in reducing annualized...

  • Other News To Note.  // BioWorld International;7/25/2012, Vol. 17 Issue 30, p5 

    This section offers news briefs on the pharmaceutical industry. Active Biotech of Lund, Sweden said that the European Medicines Agency has finished the validation process for the marketing authorization application for laquinimod in relapsing remitting multiple sclerosis. Celgene International...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics